Mylan Draws Warning Letter for GMP Violations

Drug Industry Daily
A A
Mylan was hit with an FDA warning letter for serious GMP violations at an API manufacturing facility in Andhra Pradesh, India, including improper handling of raw materials.

To View This Article:

Login

Subscribe To Drug Industry Daily